This page grew out of my Ivermectin vs. COVID-19 page. While collecting links on that subject I ran across these papers on ivermectin and cancer.
The drug shows some amazing potential as a safe, non-toxic, treatment that can be used as an alternative, or addition, to chemotherapy. Many of these papers describe ivermectin as killing cancer cells without harming healthy cells. A wondrous drug indeed!
On a cautionary note, a study has found that a significant percentage of people (16% in the small study) have a genetic mutation that inhibits the metabolism of ivermectin. In those patients, side effects such as “delirium-like behavior, agitation, aggressive attitude, and altered state of consciousness” occurred. No such side effects occurred in people without the mutation.
Papers
Cancers in general.
Repurposing Vermicide Ivermectin as Medicine in Oncology to Treat Cancer- The Silent but Accessible Role Player in Sustainable Innovation
Inhaled Ivermectin-Loaded Lipid Polymer Hybrid Nanoparticles: Development and Characterization
Ivermectin and its synthetic derivatives – A new class of anticancer agents
Ivermectin: A Multifaceted Drug With a Potential Beyond Anti-parasitic Therapy
Ivermectin A Potential Repurposed Anti-Cancer Therapeutic
Ivermectin: The future of Cancer Treatment
Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador
Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway
Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-loaded Squalene Emulsion
Ivermectin-Induced Apoptotic Cell Death in Human SH-SY5Y Cells Involves the Activation of Oxidative Stress and Mitochondrial Pathway and Akt/mTOR-Pathway-Mediated Autophagy
Synergistic Anti-tumor Effect of Dichloroacetate and Ivermectin
Ivermectin: Potential Repurposing of a Versatile Antiparasitic as a Novel Anticancer
Ivermectin, a potential anticancer drug derived from an antiparasitic drug
Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin
The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT‐TCF pathway responses in human cancer
Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug
Inhibition of TMEM16A Ca2+-activated Cl− channels by avermectins is essential for their anticancer effects
Ivermectin kills cancer cells via catastrophic changes in the endoplasmic reticulum structure
Old wine in new bottles: Drug repurposing in oncology
Long-Lasting WNT-TCF Response Blocking and Epigenetic Modifying Activities of Withanolide F in Human Cancer Cells
Lung cancer
Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer
Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells
Multiple myeloma
Assessing the potential of ivermectin against t(4;14) multiple myeloma.
Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma
Pancreatic cancer
Ivermectin suppresses pancreatic cancer via mitochondria dysfunction
Prostate cancer
Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway
Integrated analysis reveals FOXA1 and Ku70/Ku80 as direct targets of ivermectin in prostate cancer
Breast cancer
Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model
Genotoxicity and Anti-Cancer Activity of Tamoxifen and Ivermectin Loaded Chitosan Nanoparticles Against MCF-7 Cell Line
STRUCTURAL AND MOLECULAR CHARACTERIZATION OF LOPINAVIR AND IVERMECTIN AS BREAST CANCER RESISTANCE PROTEIN (BCRP/ABCG2) INHIBITORS
Ivermectin Induces Oxidative Stress and DNA Damage in Breast Cancer Cells
Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death
Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling
The PAK1-Stat3 Signaling Pathway Activates IL-6Gene Transcription and Human Breast Cancer Stem Cell Formation
Ivermectin as an inhibitor of cancer stem‑like cells
Bone cancer
Repurposing Ivermectin to augment chemotherapy’s efficacy in osteosarcoma
Ovarian cancer
Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches
Ivermectin: an ally to reverse P-glycoprotein-associated multidrug resistance in ovarian cancer
Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells
The Use of Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) to Study Ivermectin-Mediated Molecular Pathway Changes in Human Ovarian Cancer Cells
The Anti-Cancer Effects of Anti-Parasite Drug Ivermectin in Ovarian Cancer
Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine
Ivermectin inactivates the kinase PAK1 and blocks the PAK1- dependent growth of human ovarian cancer and NF2 tumor cell lines
SILAC quantitative proteomics analysis of ivermectin‐related proteomic profiling and molecular network alterations in human ovarian cancer cells
Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling
In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer
Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes
Multiomics-based energy metabolism heterogeneity and its regulation by antiparasite drug ivermectin.
Cervical cancer
Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media
Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway
Esophageal squamous cell carcinoma (ESCC)
Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway
Ivermectin suppresses tumour growth and metastasis through degradation of PAK1 in oesophageal squamous cell carcinoma
Renal cancer
Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage
Glioma
Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas
Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells
Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress
Nasopharyngeal carcinoma
Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth
Melanoma
Macrocyclic Lactones Block Melanoma Growth, Metastases Development and Potentiate Activity of Anti–BRAF V600 Inhibitors
Suppressing ROS‐TFE3‐dependent autophagy enhances ivermectin‐induced apoptosis in human melanoma cells
Gastric cancer
Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer
Liver cancer
Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice
Leukemia
Alendronate/lactoferrin-dual decorated lipid nanocarriers for bone-homing and active targeting of ivermectin and methyl dihydrojasmonate for leukemia
Codelivery of ivermectin and methyl dihydrojasmonate in nanostructured lipid carrier for synergistic antileukemia therapy
Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress
The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells
Colon cancer
Bladder cancer
Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage.
Ivermectin induces cell cycle arrest and caspase-dependent apoptosis in human urothelial carcinoma cells
Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach
Clinical Trials
Abstract PO1-19-07: A Phase I Study Accessing Immunotherapy Combination of Balstilimab and Ivermectin in Patients with Metastatic Triple Negative Breast Cancer
List of Ivermectin/Cancer trials at clinicaltrials.gov
Articles
Ivermectin Reverses Breast Cancer!
Ivermectin for Parasites, but as a PAK1 Inhibitor for Autism, Cancer and Leukemia?
